IPO pricing and final share count are placeholder; monitor amendments for price range and underwriter demand. Post-IPO, watch for execution on surgeon adoption growth (1,736 active surgeons as of June 30, 2026) and ability to sustain 42% revenue growth trajectory. The Tax Receivable Agreement creates a material cash obligation that could pressure liquidity.
Executive Summary
Centinel Spine Holdco, Inc., a pure-play total disc replacement (TDR) medical technology company, filed an S-1 registration statement for an initial public offering of Class A common stock to be listed on the NYSE under the symbol 'CNTL'. The company's prodisc platform is the only TDR platform with FDA-approved multi-level indications in both the cervical and lumbar spine. For the six months ended June 30, 2026, the company reported net revenue of $85.2 million (up 42% YoY), net income of $10.2 million (vs. a net loss of $0.5 million in the prior-year period), and Adjusted EBITDA of $15.5 million (up 137% YoY). The offering uses an Up-C structure, with proceeds intended to repay debt, fund sales/marketing, R&D, and capital expenditures.
Key Financial Metrics
Key Facts
- IPO of Class A common stock on NYSE under ticker CNTL; price range and number of shares are placeholder (undisclosed).
- Pure-play TDR company; prodisc platform is the only TDR platform with FDA-approved multi-level indications in both cervical and lumbar spine.
- Six months ended June 30, 2026: net revenue $85.2M (+42% YoY), net income $10.2M (vs. net loss of $0.5M), gross margin 82% (vs. 80%), Adjusted EBITDA $15.5M (+137% YoY).
- Year ended December 31, 2025: net revenue $132.2M (+39% YoY), net loss $4.3M (vs. net loss $12.1M), gross margin 80% (vs. 77%), Adjusted EBITDA $20.2M (+241% YoY).
- As of June 30, 2026: cash $25.1M, accumulated deficit $188.4M; total debt outstanding $136.1M (including convertible notes, term notes, and loan agreements.
- Use of proceeds: repay 2023 Credit Agreement, pay down Loan Agreement and 2025 Credit Agreement, fund sales/marketing, R&D, capital expenditures, and general corporate purposes.
- Up-C structure allows existing owners retain tax benefits; Tax Receivable Agreement requires substantial cash payments to continuing equity owners.
- Risk factors include: history of net losses, reliance on single-source manufacturers, limited commercial history, competitive pressure from Medtronic, Globus Medical, and others.
- Preliminary Q3 2026 net revenue estimated between $[?] and $[?] (vs. $31.9M in Q3 2025); operating income between $[?] and $[?] (vs. $3.4M).
Financial Impact
IPO proceeds undisclosed; net proceeds used to purchase SeriesA Common Units in Centinel LLC. Proceeds will repay ~$12.5M term notes, ~$61.4M Loan Agreement, and fund sales/marketing, R&D, and capital expenditures.
Risk Factors
- Single-source manufacturing dependencies (Hammill, Bricon, Medicoat) with up to 24-month requalification time.
- History of net losses and accumulated deficit of $188.4M; profitability not assured.
- Heavy debt load ($136.1M aggregate) with restrictive covenants; IPO proceeds used to repay debt but substantial obligations remain.
- Competitive pressure from well-capitalized players (Medtronic, Globus Medical) and risk of surgeon adoption lagging.
- Tax Receivable Agreement creates substantial future cash payment obligations that could exceed actual tax savings.
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001104659-26-114375 |
| Document: tm2613312d6_ex-filingfees.htm | 0001104659-26-114375 |
| Document: tm2613312d8_ex23-1.htm | 0001104659-26-114375 |
| Document: tm2613312d8_ex23-2.htm | 0001104659-26-114375 |
| Document: 0001104659-26-114375-index-headers.html | 0001104659-26-114375 |
| Document: 0001104659-26-114375-index.html | 0001104659-26-114375 |
| Document: 0001104659-26-114375.txt | 0001104659-26-114375 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers